Get the Stockscreener App
0.00
100.00%
-10.30
Apogee Acquisition Corp stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Apogee Acquisition Corp is a blank check company.
See More
Previous Close:
$10.30
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$10.72
Apogee Acquisition Corp Stock (AACPU) Company Profile
Name
Apogee Acquisition Corp
Sector
Industry
Phone
771.210.4643
Address
2106 HOUSE AVE SUITE 375, CHEYENNE
Compare AACPU vs LION, XXI, UMAC, CCXI, DMII
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AACPU
Apogee Acquisition Corp
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
LION
Lionsgate Studios Corp
|
11.44 | 3.35B | 2.63B | -175.60M | 11.40M | -0.7173 |
XXI
Twenty One Capital Inc
|
6.61 | 1.89B | 0 | 4.35M | 456.40K | 0.3397 |
UMAC
Unusual Machines Inc
|
23.51 | 1.15B | 17.25M | -5.64M | -40.16M | -0.3337 |
CCXI
Churchill Capital Corp Xi
|
13.17 | 686.22M | 0 | 0 | 0 | 0.0647 |
DMII
Drugs Made In America Acquisition Ii Corp
|
10.15 | 647.37M | 0 | 8.58M | -1.11M | 0.134 |
Apogee Acquisition Corp Stock (AACPU) Latest News
Apogee Therapeutics (NASDAQ: APGE) leaves Nasdaq in AbbVie cash buyout - Stock Titan
AbbVie-owned Apogee Therapeutics (APGE) pulls unsold stock - Stock Titan
Apogee Therapeutics (APGE) director-linked funds fully exit in AbbVie deal - Stock Titan
Apogee Therapeutics (APGE) CMO cashes out stock and options in AbbVie deal - Stock Titan
Director cashes out Apogee (NASDAQ: APGE) stake in AbbVie merger - Stock Titan
Apogee merger pays $135.11 per share in cash | APGE SEC FilingForm SCHEDULE 13D/A - Stock Titan
AbbVie Finalizes $10.9 Billion Acquisition of Apogee Therapeutics, Initiates Nasdaq Delisting - Kalkine Media
AbbVie Completes Acquisition of Apogee Therapeutics - Investing News Network
AbbVie Completes $10.9 Billion Acquisition of Apogee Therapeutics - Minichart
AbbVie Completes $10.9 Billion Apogee Acquisition, Reaffirms 2026 EPS Guidance - Minichart
AbbVie Closes Apogee Acquisition to Expand Immunology Portfolio - TipRanks
AbbVie seals $11B acquisition of Apogee Therapeutics (ABBV:NYSE) - seekingalpha.com
TOMI Regains Nasdaq Equity Compliance After $2.5M Debt Conversion - Minichart
Apogee Acquisition (AACP) Stock Chart and Price History 2026 - MarketBeat
ABBV climbs around 1.5% after double-digit revenue growth and Apogee acquisition - Traders Union
ARISTEIA CAPITAL, L.L.C. Initiates Position in Apogee Acquisitio - GuruFocus
Apogee Acquisition Corp Q2 2026: Net income $1.13M, EPS $0.08— 10-Q Summary - TradingView
Apogee Acquisition (AACP) faces 2027 deal-or-liquidation deadline - Stock Titan
Apogee Acquisition Corp Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AbbVie Raises $10 Billion in Debt to Fund Apogee Acquisition - Minichart
AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition - Kalkine Media
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition - Investing.com
AbbVie (NYSE: ABBV) issues new senior notes with Apogee-linked redemption - Stock Titan
AbbVie Inc Stock (ABBV) Closed Up by 3.48% on Aug 18: Key Drivers Unveiled - TradingKey
Apogee Acquisition (AACP) Stock Trends and Sentiment 2026 - MarketBeat
Apogee Acquisition Corp SEC Filing (Aug 14, 2026) - Stock Titan
Polar Asset Management (AACP) discloses 7.2% stake in Apogee Acquisition Corp - Stock Titan
Highbridge Capital Management (AACP) discloses 9.2% ownership of Apogee Acquisition - Stock Titan
Apogee Acquisition Corp (AACP) investors report 0% ownership in 13G/A exit - Stock Titan
Apogee Acquisition Corp (AACP) investor reports 7.05% holding in Class A shares - Stock Titan
Glazer Capital (AACP) discloses 5.45% Apogee Acquisition Corp stake in 13G - Stock Titan
Magnetar entities disclose 1.25M AACP shares on 13G, holding 7.05% stake - Stock Titan
Apogee Therapeutics Shareholders Endorse AbbVie Acquisition in Special Meeting - Kalkine Media
AbbVie agrees $10.9bn Apogee Therapeutics deal - Financier Worldwide
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry? - Yahoo Finance
Apogee Therapeutics Reports Q2 2026 Results and Announces Merger Agreement with AbbVie Subsidiary - Kalkine Media
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion; Apogee Reports Positive Phase 2 Zumilokibart Data and Q2 2026 Results - Quiver Quantitative
Apogee's Atopic Dermatitis Drug Shows 65.9% EASI-75 - Stock Titan
AbbVie (ABBV) Announces $10 Billion Multi-Tranche Senior Notes O - GuruFocus
AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition, Bloomberg Reports - marketscreener.com
AbbVie Announces Multi-Tranche Senior Note Offering to Finance Apogee Therapeutics Acquisition - Kalkine Media
Equity in earnings of Apogee Acquisition Corp – NASDAQ:AACPW - TradingView
Upcoming & Recent IPO'sIPOs Calendar - finance.yahoo.com
Enterprise value to EBITDA forward of Apogee Acquisition Corp – NASDAQ:AACPR - TradingView
AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps - WSJ
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc.APGE - Business Wire
AACP|Apogee Acquisition Ord Shs Class A|Price:9.997|Chg%:+0.007 - TradingKey
Apogee Acquisition Corp Revenue Breakdown – BOATS:AACPU - TradingView
Apogee Acquisition Corp Revenue Breakdown – NASDAQ:AACPR - TradingView
Apogee Acquisition Corp Revenue Breakdown – BOATS:AACPR - TradingView
Apogee Acquisition Corp Revenue Breakdown – NASDAQ:AACP - TradingView
Apogee Acquisition Corp Stock (AACPU) Financials Data
There is no financial data for Apogee Acquisition Corp (AACPU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):